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Abstract
Thrombocytopenia at diagnosis and platelet drop within the first 6 months have an adverse effect on prognosis of MDS 
patients. We therefore were interested in the association and impact on prognosis of morphologic findings of megakaryocytes 
and platelets with platelet count at diagnosis, bleeding complications, and the drop of platelets during the course of disease. 
This retrospective analysis was based on 334 MDS patients from the Duesseldorf MDS registry that were followed up for 
blood counts, bleeding, transfusion dependency, and AML evolution and correlated with morphology of the megakaryocytes 
and platelets. Thrombocytopenia was found more frequently in higher risk MDS and was associated with hypocellularity of 
the megakaryocytes in the bone marrow. Signs of bleeding were present at diagnosis in 14% and occurred during the disease 
in 48% of all MDS patients. Death due to bleeding was ranked third behind infections and AML. A decrement of platelets dur-
ing the first 6 months was associated with an inferior overall survival of 21 vs. 49 months and with a higher cumulative 2-year 
AML rate of 22.2% vs. 8.3% (p = 0.001). In a multivariate analysis, besides bone marrow blasts and karyotype, decreasing 
platelets were also associated with an inferior outcome. Signs of bleeding are present in a relevant number of MDS patients 
and account for significant morbidity and mortality in MDS. We could demonstrate the prognostic importance of decreasing 
platelets during the course of disease in all MDS patients, identifying patients at higher risk for death or AML progression.
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Introduction
Myelodysplastic syndromes are heterogeneous stem cell 
disorders characterized by dysplastic features in the bone 
marrow and various degrees of cytopenia in the peripheral 
blood that have been identified as an important prognostic 
parameter. For prognostication of patients with MDS, the 
International Prognostic Scoring System (IPSS) is used as 
the gold standard and was revised in 2012 [1, 2].
About 35–67% of all MDS patients present with throm-
bocytopenia at the time of diagnosis, whereas isolated 
thrombocytopenia occurs in less than 10% [3–6]. Thrombo-
cytopenia in MDS is mainly caused by ineffective platelet 
production as a result of disturbed proliferation and matura-
tion of megakaryocytes or their precursors [7]. Cytogenetic 
studies revealed that even in the case of a normal appearance 
on light microscopy, the majority of megakaryocytes are part 
of the MDS clone [8]. Although it is well known that the 
initial platelet count is an important prognostic parameter, 
data on the clinical course of the patients with low platelets 
during the course of the disease are sparse. Besides AML 
evolution, infections and bleeding complications are the 
most frequent causes of death [9]. Death due to bleeding 
complications is found not only in patients with low plate-
let counts but also in patients with higher or even normal 
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platelets, suggesting underlying platelet dysfunction [5, 10]. 
There is evidence that the kinetics of cytopenia in lower risk 
MDS patients and the occurrence of red blood cell transfu-
sion dependency have a prognostic impact [11, 12]. To bet-
ter elucidate the influence of transfusion dependency at the 
time of diagnosis, during the course of the disease and, most 
importantly, the prognostic impact with regard to survival 
and risk of progression to AML of decreasing platelet counts 
during the course of the disease across all MDS subtypes are 
the major aims of this study. We correlated these findings 
with morphological findings in the blood and in the bone 
marrow.
Methods
This retrospective analysis is based on the Düsseldorf MDS 
registry, which was initiated in 1982 and maintained since 
then. Diagnostic procedures were the same as reported 
in our previous studies [13, 14]. In total, 334 of patients 
included in the registry between 2008 and 2015 were fol-
lowed up closely for blood counts every 3 months includ-
ing morphology of the platelets in the differential blood 
count, transfusion need, and for survival and AML evolu-
tion. Only patients with at least one follow-up blood count 
were included. All blood and bone marrow smears were 
examined by the same investigator (U.G.) at our hemato-
logic laboratory. The morphological diagnosis was made 
according to the proposals of the 2016 WHO classification 
[15]. Patients with CMML were also included in the analy-
sis. A peripheral blood smear was examined to determine 
the differential white blood count, recognize circulating 
blast cells, and assess platelet morphology. In the marrow, 
a differential count of 500 nucleated cells was performed to 
determine the proportion of medullary blasts. Megakary-
opoiesis was analyzed with regard to maturation defects and 
dysplastic features of megakaryocytes. Dysmegakaryopoie-
sis was diagnosed if at least 10 out of 25 megakaryocytes 
were micromegakaryocytes or mononuclear megakaryo-
cytes, or had multiple widely separated nuclei. Maturation 
defects included all other features representing disturbed 
maturation without clear dysmegakaryopoietic criteria as 
previously described [5]. Cytogenetic analysis by meta-
phase karyotyping was performed in the Institute of Human 
Genetics, Heinrich-Heine University, Duesseldorf. An iso-
lated thrombocytopenia was considered if the platelet count 
was < 100,000/µl, the hemoglobin value was > 10 g/dl, and 
the ANC was > 800/µl. If possible, patients were followed 
for platelet transfusion requirement triggered by bleeding 
signs or thrombocytopenia < 10,000/µl, signs of bleeding, 
and causes of death. Patients were considered platelet trans-
fusion dependent if platelets had to be administered at least 
once per month. Transfusion requirement during allogeneic 
stem cell transplantation, treatment with hypomethylating 
agents, or induction chemotherapy was not regarded as trans-
fusion dependency and therefore was not considered for the 
analysis. For survival analysis, patients who received alloge-
neic stem cell transplantation (n = 55, 16.5%) were censored 
at the time of transplantation. Survival probabilities were 
estimated using the Kaplan–Meier method and compared by 
the log-rank test, when no time-dependent covariates were 
present. To investigate the impact of a decrease of platelet 
counts, a landmark analysis was performed 6 months after 
diagnosis (± 1 months) [16]. This analysis included those 
patients, who survived for more than 7 months, who had 
a second blood count within this time and had an initial 
platelet count > 20,000/µl and were not transfusion depend-
ent. Cumulative incidences of AML were estimated under 
the presence of the competing risk of death. For the multi-
variate models, missing covariate values were imputed by 
fully conditional specification: accommodating the substan-
tive model. One hundred datasets were generated using 25 
iterations each [17]. Clinical and hematological data at the 
time of diagnosis were compared using the χ-square and 
Wilcoxon rank-sum test. A two-sided p-value of less than 
0.05 was considered statistically significant. For all statisti-
cal analyses, SPSS version 25 and R 3.5.1 were used.
Results
Patient characteristics
Looking at the entire cohort of 334 patients, 199 were male 
(60%) and the median age was 68 years (range 22–87). After 
a median follow-up of 24 months (range 1–187 months), 161 
patients have died (48%). From the entire patient cohort, 
76 (23%) patients progressed into acute myeloid leukemia 
(AML). When categorizing patients according to the initial 
platelet count using the IPSS-R cutoffs, 106 patients pre-
sented with platelets > 100,000/µl (32%), 122 had a plate-
let count between 50,000 and 100,000/µl (37%), and 101 
patients (31%) presented with platelets < 50,000/µl, respec-
tively. Only 26 patients (7.8%) had severe thrombocytope-
nia of < 20,000/µl. Baseline characteristics are presented in 
Table 1. An isolated thrombocytopenia at the time of diag-
nosis was present in 77 patients (21%).
Looking at the distribution of patients according to the 
WHO 2016 classification, we found in the unfavorable risk 
category MDS EB-2 a high number of patients with decreas-
ing initial platelet counts. In accordance to this finding, the 
amount of higher risk MDS according to the IPSS-R also 
increased with decreasing initial platelet count. The corre-
lation of increasing thrombocytopenia and increasing risk 
category according to the IPSS-R was even more evident 
when looking at the small group of patients with transfusion 
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dependency at the time of diagnosis with 41% classified as 
very high risk.
Forty-five patients (14%) were transfusion dependent 
at the time of diagnosis and 92 patients (27%) developed 
transfusion dependency during the course of the disease. 
Information about the dimension of transfusion dependency 
was available in 297 patients. The median number of trans-
fused platelet units was 17 (range 1–177). A total of 133 
patients received none and 133 patients 1–50 platelet units; 
31 patients were heavily transfused with > 50 units.
A platelet decrement of at least 25% from the initial 
platelet count within the first 6 months after diagnosis 
(± 1 months) was found in 70 patients (21%). In this cohort, 
we also found a higher number of patients with higher risk 
MDS than in those patients without decreasing platelets 
(Table 2).
Bleeding
Information about signs of bleeding at the time of diagno-
sis and during follow-up were available from 172 (52%) 
and 193 (58%) patients, respectively. Among those, 24 
patients (14%) showed signs of bleeding at diagnosis and 
92 patients (48%) developed bleeding complications during 
the follow-up period. Among both groups, petechia was the 
most frequently observed sign of bleeding (54% and 36%, 
respectively). There was no correlation between IPSS-R risk 
Table 1  Baseline characteristics
TD transfusion dependency
* Patients with SLD-RS (n = 6) and MLD-RS (n = 2) are included in SLD and MLD
All
n = 334








Sex male 199 (60%) 59 (55%) 83 (66%) 57 (56%) 29 (64%)
Female 135 (40%) 48 (45%) 42 (34%) 45 (44%) 16 (36%)
med. age 68 (23–87) 68 (45–87) 69 (23–87) 65 (35–83) 66 (39–84)
WHO n = 324 n = 45
SLD* 17 (5.1%) 6 (5.6%) 4 (3.3%) 7 (7.1%) 1 (2.2%)
MLD* 134 (41.4%) 49 (45.8%) 44 (37.0%) 41 (41.8%) 17 (37.8%)
5q- 11 (3.4%) 9 (8.4%) 2 (1.7%) 0 0
EB-1 52 (16.0%) 14 (13.1%) 28 (23.5%) 10 (10.2%) 5 (11.1%)
EB-2 62 (19.1%) 12 (11.2%) 23 (19.3%) 27 (27.6%) 13 (28.9%)
CMML-1 30 (9.3%) 14 (13.1%) 12 (10.1%) 4 (4.1%) 3 (6.7%)
CMML-2 12 (3.7%) 2 (1.9%) 5 (4.2%) 5 (5.1%) 4 (8.9%)
MDS-U 6 (1.8%) 1 (0.9%) 1 (0.8%) 4 (4.1%) 2 (4.4%)
IPSS-R n = 256 n = 34
Very low 27 (10.5%) 16 (19%) 10 (10.2%) 1 (1.4%) 1 (2.9%)
Low 66 (25.8%) 35 (41.7%) 15 (15.3%) 16 (21.6%) 3 (8.8%)
Intermediate 60 (23.4%) 20 (23.8%) 28 (28.6%) 12 (16.2%) 6 (17.6%)
High 51 (19.9%) 10 (11.9%) 21 (21.4%) 20 (27.0%) 10 (29.4%)
Very high 52 (20.3%) 3 (3.6%) 24 (24.5%) 25 (33.8%) 14 (41.2%)










Sex male 89 (61%) 45 (59%) 44 (63%)
Female 57 (39%) 31 (41%) 26 (37%)
med. age 69 (42–84) 68 (45–84) 69 (42–84)
WHO n = 143 n = 74 n = 69
SLD 6 (4.2%) 4 (5.4%) 2 (2.9%)
MLD 61 (42.7%) 33 (44.6%) 28 (40.6%)
5q- 6 (4.2%) 5 (6.8%) 1 (1.4%)
EB-1 22 (15.4%) 15 (20.3%) 7 (10.1%)
EB-2 25 (17.5%) 9 (12.2%) 16 (23.2%)
CMML-1 15 (10.5%) 5 (6.8%) 10 (14.5%)
CMML-2 6 (4.2%) 3 (4.1%) 3 (4.3%)
MDS-U 2 (1.4%) 0 2 (2.9%)
IPSS-R n = 118 n = 58 n = 60
Very low 12 (10.2%) 7 (12.1%) 5 (8.3%)
Low 34 (28.8%) 21 (36.2%) 13 (21.7%)
Int 28 (23.7%) 13 (22.4%) 15 (25.0%)
High 24 (20.3%) 11 (19.0%) 13 (21.7%)
Very high 20 (17.0%) 6 (10.3%) 14 (23.3%)
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category and the presence of bleeding at diagnosis nor dur-
ing the disease. However, as expected, the initial platelet 
count was correlated with signs of bleeding at the time of 
diagnosis (p = 0.002). When looking at the patients with a 
drop of the platelet count and an occurrence of bleeding, 69 
(61%) developed bleeding complications during the course 
of the disease.
Causes of death were known from 120 patients (75%). 
Death was disease related in 95%, with death due to infec-
tion as the most frequent cause of death in 35%, followed 
by death due to AML in 19%. Fatal bleeding complications 
occurred in 15 patients (9.3%). Of note, only one patient who 
presented with signs of bleeding at diagnosis died due to 
bleeding complications. The majority of patients that devel-
oped signs of bleeding during the course of the disease died 
due to other reasons (n = 48, 76%). Looking at those patients 
with isolated thrombocytopenia, causes of death were com-
parable to patients with a bi- or tricytopenia.
Platelet count and morphology
In the next step, we investigated a potential correlation 
between platelet counts and morphological findings. The 
distribution of morphological findings in the peripheral 
blood as well as in the bone marrow according to the platelet 
count is shown in Table 3. Of note, we found a significant 
correlation between the histologic and cytologic analyses 
when looking at the cellularity of the megakaryopoiesis 
(OR 14.54; 95%CI 6.03–35.07). Additionally, hypocellular 
megakaryopoiesis was significantly correlated with throm-
bocytopenia (OR 4.29, 95%CI 2.55–7.21). Of note, we could 
not find a correlation between the cellularity of the mega-
karyopoiesis and the presence of dysmegakarypoiesis, but 
the presence of dysmegakaryopoiesis in the bone marrow 
reflects an abnormal platelet morphology in the peripheral 
blood (OR 2.95; 95%CI 1.03–8.44), although we could not 
identify a specific dysplastic feature of the megakaryocytes 
associated with abnormal platelet morphology. Morphologi-
cally abnormal platelets were correlated with transfusion 
dependency at diagnosis (OR 10.03; 95%CI 1.29–78.11). 
The presence of signs of bleeding at diagnosis as well as 
the frequency of AML progression correlated neither with 
dysplastic features of the megakaryopoiesis nor with plate-
let morphology or cellularity of the megakaryocytes at 
diagnosis.
Information on platelet morphology at diagnosis and at 
the time when platelets decreased was available from 47 
patients. In this small cohort, we were not able to find a 
correlation between the morphology of the platelets and the 
progression of thrombocytopenia at the two times.
Prognosis
Patients with a normal platelet count had the best progno-
sis with a median survival of 70 months. In comparison, 
patients with platelet counts between 50,000 and 100,000/µl, 
and with platelet counts < 50,000/µl had a significantly worse 
survival probability with medians of 33 and 31 months 
(p = 0.003, Fig. 1). In line with this finding, platelet transfu-
sion dependency at the time of diagnosis decreased survival 
probabilities in our cohort significantly (p = 0.02) with a 
median survival of 15 vs. 37 months, respectively. An iso-
lated thrombocytopenia at the time of diagnosis was associ-
ated with a better prognosis in comparison to bi- or tricyto-
penia (median survival: 46 vs. 24 months, p < 0.0001). The 
presence of dysmegakaryopoietic features in the bone mar-
row was also correlated with prognosis (29 vs. 65 months, 
p = 0.02), whereas megakaryocytic cellularity, dysmor-
phologic features of the thrombocytes, and the presence of 
bleeding at diagnosis showed a tendency for inferior survival 
without being statistically significant (data not shown).
Table 3  Morphology of 
thrombocytes in the peripheral 
blood and megakaryocytes
All Thrombocytes/µl
 > 100,000 50–100,000  < 50,000
Suspicious platelet morphology 48 (14.4%) 28 (63.6%) 14 (26.9%) 6 (14.0%)
Platelet anisometry 39 (11.7%) 24 (22.4%) 11 (8.8%) 4 (3.9%)
Giant platelets 26 (7.8%) 13 (12.1%) 9 (7.2%) 4 (3.9%)
Any sign of dysmegakapoiesis 204 (61.1%) 66 (76.7%) 74 (71.8%) 64 (72.7%)
Maturation defects 81 (24.3%) 25 (29.1%) 24 (24.2%) 32 (37.6%)
Micromegakaryocytes 86 (25.7%) 28 (32.6%) 33 (32.7%) 25 (29.1%)
Mononuclear forms 95 (28.4%) 32 (37.2%) 35 (35%) 28 (32.9%)
Multiple separated nuclei 97 (29.0%) 30 (34.9%) 33 (33.3%) 34 (40.5%)
Megakaryocytic cellularity n = 285 n = 89 n = 105 n = 93
Hypocellular 88 (30.9%) 14 (15.7%) 24 (22.9%) 50 (54.9%)
Normocellular 123 (43.2%) 47 (52.8%) 48 (45.7%) 28 (30.8%)
Hypercellular 74 (26.0%) 28 (31.5%) 33 (31.4%) 13 (14.3%)
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After a median follow-up of 24 months, 76 of the patients 
had progressed into an AML. Median time to AML evolu-
tion was not reached, but after 2 years, the cumulative inci-
dence was 23% (95%CI 17.9–27.8%).
Prognostic impact of decreasing platelets
After demonstrating the prognostic relevance of the plate-
let count at diagnosis, we were interested in the prognostic 
impact of the decreasing platelets during the course of the 
disease. Performing a landmark analysis, we could demon-
strate an inferior survival in patients with a platelet drop. 
We compared them with those patients who survived for 
more than 7 months, and who had a second blood count 
within this time and had an initial platelet count > 20,000/µl 
but remained stable with the platelet count. Figure 2 shows 
the initial platelet count and platelet count at landmark for 
all patients depending on outcome. This survival disad-
vantage was found in the entire patient cohort as well as 
when excluding patients receiving an allogeneic stem cell 
Fig. 1  Overall survival accord-
ing to initial platelet count. 
Cumulative survival prob-
ability according the to the 
initial platelet count. Patients 
with platelet counts between 
50,000 and 100,000/µl, and with 
platelet counts < 50,000/µl had 
a significantly worse survival 
probability with medians of 33 
and 31 months in comparison 
to a normal platelet count with 
70 months OS (p = 0.003)
Fig. 2  Initial platelet count and 
platelets at landmark depending 
on outcome. Scatter plot of the 
initial platelet count and plate-
lets at landmark for each patient 
depending on outcome (alive in 
blue and dead in red)
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transplantation or induction chemotherapy (median sur-
vival: 49 vs. 21 months and 38 vs. 17 months, respectively, 
p < 0.001; Fig. 3). We then performed the landmark analysis 
separately for patients with lower risk MDS with a medul-
lary blast count < 5% and for those with higher risk disease 
with a blast count > 5%. Median survival times for patients 
with < 5% BM blasts with platelet drop were 25 months and 
58 months without platelet drop, respectively (p = 0.009). 
In the higher risk cohort, we could confirm the prognos-
tic influence of an early platelet drop with median survival 
times of 15 and 33 months, respectively (p = 0.003).
Within the first 6 months after diagnosis, 29 patients 
have progressed into AML. As we were interested in the 
clinical course of the disease in patients after our land-
mark, we excluded these patients from the following 
analysis. When only looking at those patients that devel-
oped AML later, the 2-year cumulative incidence of AML 
evolution differed significantly between those patients 
with decreasing platelets of at least 25% at landmark of 
6 months and without decreasing platelets (22% [95%CI 
14–35%] and 8.3% [95%CI 3.5–19%], p < 0.001, Fig. 4). 
When looking at the lower risk MDS patients, the 2-year 
cumulative incidence of AML evolution was 16% [95%CI 
6.4–38%] for patients with decreasing platelets and 3.4% 
[95%CI 0.5–22%] for patients without decreasing plate-
lets (p = 0.19). In patients with > 5% bone marrow blasts, 
AML incidences were 41% [95%CI 24–64%] vs. 18% 
[95%CI 7.1–41%], respectively (p = 0.09). AML progres-
sion was observed in 14 patients (21%) at the same time as 
Fig. 3  Overall survival after 
landmark of 6 months. Cumula-
tive survival of patients with 
and without a platelet decre-
ment. A platelet decrement of 
at least 25% within the first 
6 months (± 1 months) after 
diagnosis was significantly 
associated with an inferior 
survival of 21 vs. 49 months, 
respectively (p < 0.001)
Fig. 4  AML progression after 
landmark for all patients. 
Cumulative incidence of AML 
evolution in patients with and 
without platelet decrement. The 
2-year cumulative incidence of 
AML evolution differed sig-
nificantly between patients with 
decreasing platelets of at least 
25% at landmark of 6 months 
and without decreasing platelets 
(8.3% vs. 22.2%, p < 0.001)
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the decrease of platelets, in 15 patients before the platelet 
decreased, and in 38 patients after the platelet decreased.
To further elucidate the influence of decreasing platelets, 
we performed a multivariate analysis. We identified higher 
age (HR 1.04; 95%CI 1.01–1.06; p = 0.005), a medullary 
blast count > 5% (HR 2.71; 95%CI 1.73–4.26, p < 0.0001), 
and a higher risk karyotype (HR 2.26; 95%CI 1.26–4.07; 
p = 0.007) significantly predicting survival besides the 
platelet drop (HR 2.35; 95%CI 1.45–3.79, p = 0.0005). In 
a cause-specific hazard risk model for AML progression, 
platelet drop, a medullary blast count > 5%, and a high-risk 
karyotype were significantly correlated with AML evolution 
(HR 3.57; 95%CI 1.70–7.47, p = 0.0007; HR 4.76; 95%CI 
2.53–8.96, p < 0.0001; and HR 3.30; 95%CI 1.63–6.69, 
p = 0.0009, respectively; Fig. 5).
Discussion
Thrombocytopenia is a frequent finding in MDS patients. 
Therefore, with our study, we wanted to shed more light 
on the relationship between platelet counts, morphology, 
Fig. 5  Forest plot of HR for 
overall survival (a) and AML 
evolution (b). a Significant 
predictors for survival were 
age > 65 years, a medullary 
blast count > 5%, a high-
risk karyotype, and platelet 
drop > 25% within 6 months 
after diagnosis. b In a cause-
specific hazard risk model for 
AML progression, platelet drop, 
a medullary blast count > 5%, 
and a high-risk karyotype were 
significantly correlated with 
AML evolution
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bleeding complications, and prognostic impact of platelet 
counts during the course of the disease. We could demon-
strate a correlation between platelet count and cellularity 
of the megakaryocytes in the bone marrow. Furthermore, 
bleeding complications as well as fatal bleedings can occur 
in all MDS patients, not only in those with a severe throm-
bocytopenia. Third, an early drop of the platelet count during 
the course of the disease is a strong parameter for an adverse 
prognosis. To our knowledge, we are the first who could 
demonstrate the negative impact of platelet drop not only in 
low-risk patients as the Duesseldorf MDS registry allows a 
closer look on the platelet counts over the time of several 
different MDS patients.
This analysis is based on 334 MDS patients with 60% 
male patients, comparable to other studies [2, 11]. In our 334 
MDS patients with available platelet counts and transfusion 
need during the disease, we could show that thrombocyto-
penia is a frequent finding in MDS patients with about 2/3 
of the patients presenting with platelets of < 100,000 at the 
time of diagnosis. In our cohort, we found a higher number 
of patients with a thrombocytopenia than in other publica-
tions from Greenberg with 40% and Neukirchen with 43% 
[2, 5]. This finding may be explained by the fact that we 
focused on those patients who were seen regularly at our 
center and whose repeated blood counts were available. This 
closely followed patient cohort comprising a higher num-
ber of high-risk patients (50%). Likewise, the percentage 
of patients with an isolated thrombocytopenia (26%) was 
higher than that in previously published studies with 12% [6, 
18]. Of note, in different studies published, varying cutoffs 
were used, especially, different hemoglobin levels of 10 g/
dl and 12 g/dl, respectively. In our cohort, there was only a 
small number of patients with very severe thrombocytope-
nia < 20,000/µl. Therefore, an evaluation of those patients 
separately did not reveal additional information.
In MDS, there is no clear correlation between distinct 
dysplastic features in the bone marrow and peripheral 
blood counts, although with an increasing number of dif-
ferent signs of dysplasia the cell counts were lower [19]. 
We therefore analyzed the morphological features of our 
cohort in detail.
Although histology remains the gold standard for the 
evaluation of bone marrow, cellularity results of cytology 
and histology were comparable in our cohort, when restrict-
ing this analysis to the cellularity of the megakaryocytes. 
This fact may be due to an easy recognition of megakaryo-
cytes in the bone marrow. The impact of bone marrow cel-
lularity on prognosis is still a matter of debate. Some studies 
could show a different prognosis for patients with hypocel-
lular bone marrow and suggest that hypocellular MDS 
could be considered a separate entity, whereas others did 
not [20–22]. Patients with a hypocellular bone marrow pre-
sent more often with lower peripheral blood counts [22, 23]. 
When focusing on the cellularity of the megakaryocytes, 
we could demonstrate a clear correlation between hypocel-
lularity of the megakaryocytes and thrombocytopenia in 
the peripheral blood as a result of the disturbed megakaryo-
cytic differentiation and maturation. This finding proceeds 
with the occurrence of morphologically abnormal platelets 
in the peripheral blood. In summary, we can state that the 
evaluation of dysplastic features has an important impact on 
diagnostic procedures of MDS patients but is not an appro-
priate feature for the evaluation of the prognosis during the 
course of the disease. In contrast to our previous publication 
on a larger cohort, we could not demonstrate a correlation 
between signs of dysmegakaryopoiesis or dysplastic platelet 
morphology and signs of bleeding [5]. We suppose this is 
due to the relatively small cohort currently analyzed.
A platelet transfusion dependency at the time of diag-
nosis was found in 14% and occurred during the course of 
the disease in 27% of the patients, comparable to previously 
published data from the Duesseldorf MDS registry [5]. 
Although the aim of regular transfusion is the prevention of 
bleeding complications, 32% of all patients succumbed from 
signs of bleeding either at diagnosis or during the course of 
the disease and 13% died due to bleeding complications. 
The observed rate of death due to bleeding complications is 
also in line with our previously published data. As expected, 
platelet count at diagnosis, as well as thrombocytopenia dur-
ing the course of the disease, was significantly correlated 
with the occurrence of bleeding. But, of note, even about 
30% of the patients with higher platelet counts at diagnosis 
presented signs of bleeding during the disease. This finding 
reflects an additionally underlying platelet dysfunction in 
MDS patients that may also influence the risk of bleeding 
complications. The most common functional abnormality 
of the platelet function in MDS is impaired or absent aggre-
gation; in detail, platelets of MDS patients show a general 
defect in integrin-dependent aggregation [10]. Remarkably, 
the majority of patients that developed signs of bleeding 
during the disease did not die due to fatal bleeding, maybe 
reflecting an effective transfusion regime. Nachtkamp et al. 
analyzed the causes of death in 2877 MDS patients. Death 
due to bleeding complications was with 9.8%, ranking third 
following AML and infections, too [9].
The prognostic relevance of thrombocytopenia in MDS 
patients is well known and could be confirmed by our data. 
Additionally, in line with previously published studies, 
we could show that overall survival is superior with the 
occurrence of isolated thrombocytopenia. This reflects a 
more aggressive disease, when more cell lines are affected. 
Besides known prognostic parameters as cell counts at 
diagnosis, we could show that the drop of platelets during 
the disease is an important factor associated with inferior 
prognosis regarding survival as well as AML transformation 
rates. Currently, only few data on the impact of worsening 
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of the platelet count during the disease are available. On a 
large cohort from the European Leukemia Net MDS registry, 
a relative platelet drop > 25% and the presence of a transfu-
sion dependency for red blood cells 6 months after diagno-
sis could identify lower risk MDS patients with an adverse 
prognosis [11]. In this work, a platelet drop within 6 months 
occurred in 21.7% of the low-risk patients. In our cohort, we 
observed a platelet drop in 48%, reflecting our cohort with 
low- and high-risk patients. We were able to confirm the 
prognostic relevance of a relative drop of platelets of ≥ 25% 
during the first 6 months not only in lower risk patients but 
also in higher risk patients. For the cumulative overall sur-
vival, an early platelet drop was significantly associated with 
an adverse prognosis in lower risk as well as in higher risk 
patients. Due to the smaller number of patients in our cohort 
than in the work from the EUMDS registry, we could not 
stratify for all IPSS-R subgroups. We therefore chose the 
bone marrow blast count of 5% as a cutoff for defining high- 
and low-risk disease. For AML progression, cumulative 
incidences at 2 years were lower in patients without a plate-
let drop irrespective of the bone marrow blast count. We 
obtained similar results, when setting the cutoff for the drop 
of platelets to 50% (data not shown). This negative impact 
on prognosis was demonstrated in untreated BSC patients as 
well as in the entire patient cohort that comprises patients 
treated with induction chemotherapy and hypomethylating 
agents, as well as allogeneic stem cell transplantation. Com-
pared to the data from Itzykson and colleagues, the overall 
survival rates as well as the incidences of AML progression 
were higher in our cohort, reflecting the higher number of 
patients with high-risk MDS [11]. Factors associated with an 
early platelet drop in a multivariate analysis were higher age, 
higher risk IPSS-R, and initially existing thrombocytopenia. 
The drop of platelets within the first 6 months increased the 
cause-specific hazard for AML progression as well as the 
overall mortality hazard, reflecting the importance of chang-
ing parameters during the course of the disease. Of inter-
est, when looking at the patients either with development of 
transfusion dependency for platelets or with an early drop of 
platelets and the IPSS-R categories at the time of diagnosis, 
we found no correlation between the IPSS-R risk and the 
worsening of the peripheral blood counts (data not shown). 
This finding can be regarded as a limitation of static risk 
models as the IPSS-R that cannot be adapted to the clinical 
course of each individual patient. Therefore, dynamic risk 
models that recognize disease parameters during the course 
of the disease of each patient are warranted to better identify 
the individual risk for progression or death and thus helping 
in treatment decision making.
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